Dallas, Texas 01/31/2014 (FINANCIALSTRENDS) – On 13th January, the $327 million market capped, development stage drug maker Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported updates on its pipeline of target compounds that it has been developing to treat chronic hepatitis C (HCV).
Dr. Milind Deshpande, President and Chief Executive Officer of Achillion has been quoted to have said that, ” With the emerging safety and in vitro data on ACH-3422, a uridine nucleotide inhibitor of NS5B polymerase, and the 12-week clinical activity reported with ACH-3102, our Phase 2, pan-genotypic, second-generation NS5A inhibitor, we believe that our HCV compounds are well-positioned to achieve positive results in the clinical studies we plan to initiate throughout 2014. We believe we have sufficient capital to fund our operations into 2016 and achieve a number of value-creating milestones throughout this year with our HCV assets.”
The development stage drug firm boasted of cash reserves of close to $150 million at the end of 2013, which it has indicated would broadly support the development of commercially viable therapies designed to alleviate the suffering of patients with chronic hepatitis C by administering their short duration treatments.
With respect to the 2014 Milestones, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported the following roadmaps. For its target drug “ACH-3422: HCV Nucleotide NS5B Polymerase Inhibitor” the drug maker wants to progress its current pre-clinical trials into clinical tests with the phase 1 of these trials slated to being in mid 2014 and hopes to report initial results by third quarter of this year.
On its other lead drug candidate” ACH-3102 + sofosbuvir”, the drug maker has reported that it plans to kick start its phase 2 pilot study in the April to June’ 14 time frame and has planned a 8 week test period in which the chronic hepatitis C patients will be administered this test drug.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.